Cancer research needs a better map

Boehm, Jesse S.; Garnett, Mathew J.; Adams, David J.; Francies, Hayley E.; Golub, Todd R.; Hahn, William C.; Iorio, Francesco; McFarland, James M.; Parts, Leopold; Vazquez, Francisca

doi:10.1038/d41586-021-00182-0

COMMENT
26 January 2021

Cancer research needs a better map

It is time to move beyond tumour sequencing data to identify vulnerabilities in cancers.

Jesse S. Boehm⁰,
Mathew J. Garnett¹,
David J. Adams²,
Hayley E. Francies³,
Todd R. Golub⁴,
William C. Hahn⁵,
Francesco Iorio⁶,
James M. McFarland⁷,
Leopold Parts⁸ &
…
Francisca Vazquez⁹

Jesse S. Boehm
1. Jesse S. Boehm is a leader of the Cancer Dependency Map project at the Broad Institute in Cambridge, Massachusetts, USA.
View author publications

You can also search for this author in PubMed Google Scholar
Mathew J. Garnett
1. Mathew J. Garnett is a leader of the Cancer Dependency Map project at the Wellcome Sanger Institute in Hinxton, UK.
View author publications

You can also search for this author in PubMed Google Scholar
David J. Adams
1. David J. Adams is a leader of the Cancer Dependency Map project at the Wellcome Sanger Institute in Hinxton, UK.
View author publications

You can also search for this author in PubMed Google Scholar
Hayley E. Francies
1. Hayley E. Francies is a leader of the Cancer Dependency Map project at the Wellcome Sanger Institute in Hinxton, UK.
View author publications

You can also search for this author in PubMed Google Scholar
Todd R. Golub
1. Todd R. Golub is a leader of the Cancer Dependency Map project at the Broad Institute in Cambridge, Massachusetts, USA; and a cancer biologist at the Dana-Farber Cancer Research Institute in Boston, Massachusetts, USA.
View author publications

You can also search for this author in PubMed Google Scholar
William C. Hahn
1. William C. Hahn is a leader of the Cancer Dependency Map project at the Broad Institute in Cambridge, Massachusetts, USA; and a cancer biologist at the Dana-Farber Cancer Research Institute in Boston, Massachusetts, USA.
View author publications

You can also search for this author in PubMed Google Scholar
Francesco Iorio
1. Francesco Iorio is a leader of the Cancer Dependency Map project at the Wellcome Sanger Institute in Hinxton, UK; and a computational cancer biologist at the Human Technopole in Milan, Italy.
View author publications

You can also search for this author in PubMed Google Scholar
James M. McFarland
1. James M. McFarland is a leader of the Cancer Dependency Map project at the Broad Institute in Cambridge, Massachusetts, USA.
View author publications

You can also search for this author in PubMed Google Scholar
Leopold Parts
1. Leopold Parts is a leader of the Cancer Dependency Map project at the Wellcome Sanger Institute in Hinxton, UK.
View author publications

You can also search for this author in PubMed Google Scholar
Francisca Vazquez
1. Francisca Vazquez is a leader of the Cancer Dependency Map project at the Broad Institute in Cambridge, Massachusetts, USA.
View author publications

You can also search for this author in PubMed Google Scholar

A coloured scanning electron micrograph of a spheroid pancreatic cancer cell covered in nodules — There are few models to study rare cancers. Credit: Steve Gschmeissner/SPL

Access through your institution

Buy or subscribe

Almost 15 years ago, scientists and clinicians set out to characterize genomes of tumours from thousands of patients. The result? The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC). Nearly every targeted cancer drug approved over the past decade has drawn from the data sets generated by these efforts. This information is now also providing clues to triangulate which individuals can benefit from new types of drug, such as pembrolizumab and nivolumab, which help the immune system to fight cancer. TCGA generated more than 2.5 petabytes of data measuring mutations, gene expression and protein levels across 33 cancer types. It catalysed innovation in DNA sequencing technology and genome analysis. It ultimately collected data from some 11,000 patients — data that thousands of researchers use. This work redefined cancers on the molecular level, and painted a picture of the mutations that occur in common tumour types.

Access options

Access through your institution

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 589, 514-516 (2021)

doi: https://doi.org/10.1038/d41586-021-00182-0

References

Zehir, A. et al. Nature Med. 23, 703–713 (2017).
Article PubMed Google Scholar
Stockley, T. L. et al. Genome Med. 8, 109 (2016).
Article PubMed Google Scholar
Tsherniak, A. et al. Cell 170, 564–576 (2017).
Article PubMed Google Scholar
Behan, F. M. et al. Nature 568, 511–516 (2019).
Article PubMed Google Scholar
Corsello, S. M. et al. Nature Cancer 1, 235–248 (2020).
Article PubMed Google Scholar
Weinstein, I. B. & Joe, A. Cancer Res. 68, 3077–3080 (2008).
Article PubMed Google Scholar
Hong, D. S. et al. N. Engl. J. Med. 383, 1207–1217 (2020).
Article PubMed Google Scholar
Luo, J., Solimini, N. L. & Elledge, S. J. Cell 136, 823–837 (2009).
Article Google Scholar
Garnett, M. J. et al. Nature 483, 570–575 (2012).
Article PubMed Google Scholar
Iorio, F. et al. Cell 166, 740–754 (2016).
Article PubMed Google Scholar
Barretina, J. et al. Nature 483, 603–607 (2012).
Article PubMed Google Scholar
Haverty, P. M. et al. Nature 533, 333–337 (2016).
Article PubMed Google Scholar
Dempster, J. M. et al. Nature Commun. 10, 5817 (2019).
Article PubMed Google Scholar
Feldman, D. et al. Cell 179, 787–799 (2019).
Article PubMed Google Scholar
Rozenblatt-Rosen, O., Stubbington, M. J. T., Regev, A. & Teichmann, S. A. Nature 550, 451–453 (2017).
Article PubMed Google Scholar
Haibe-Kains, B. et al. Nature 504, 389–393 (2013).
Article PubMed Google Scholar